Nimbus Therapeutics’ Chief Scientific Officer, Rosana Kapeller, has blogged about the Über disruption coming to biotech . Here, their Chief Business Officer discusses his revelations (mostly positive) from operating his company in the Uber model — with 150 people on the payroll, most being freelance consultants, and only 25 employees.  Such staffing nimbleness is made possible by the burgeoning biotech gig economy we find ourselves in. (LifeSciVC)